6 papers in the library · 286 citations · publishing 1996-2023
BMJ May 2, 2023 Leslie A. King, David Nutt, David E. Nichols 1 citation
Regulation of clinical research on schedule 1 drugs with therapeutic potential should be reviewed, argue Leslie King, David Nutt and David Nichols
Drug Testing and Analysis July 1, 2014 Simon D. Brandt, Leslie A. King, Michael Evans‐brown 164 citations
This special issue provides a multidisciplinary snapshot of recent developments of the broader, arguably phenomenal, changes to the drug market that have occurred in the past decade related to the rise of the new drug phenomenon. This change is largely a result of the growing commodification by entrepreneurs, and increasingly, by criminal groups, of a huge range of psychoactive substances not...
Drug Testing and Analysis August 15, 2013 Leslie A. King, István Ujváry, Simon D. Brandt 8 citations
The concept of a 'derivative' is used widely in chemistry, where its precise meaning depends on the circumstances. However, numerous examples of derivative also occur in domestic drugs legislation, some of which stem from the 1961 United Nations Single Convention on Narcotic Drugs. There is a commonly held view that only 'first-order' derivatives should be considered: substances that can be...
Nature reviews. Neuroscience June 12, 2013 David Nutt, Leslie A. King, David E Nichols
Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4-methylenedioxy-N-methylamphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and...
Drug Testing and Analysis July 1, 2011 Leslie A. King, Andrew T. Kicman 99 citations
This special issue of DTA is devoted to what were once known as 'designer drugs', but in recent times have been described informally as 'legal highs'. The preferred term, as adopted by the European Community in 2005[1], [2] is 'new psychoactive substances'. They are defined as 'Narcotic or psychotropic drugs that are not scheduled under the United Nations 1961 or 1971 Conventions, but which may...
BMJ August 17, 1996 David Shewan, Phil Dalgarno, Leslie A. King 14 citations
EDITOR,—There is increasing concern over the toxic1 and neurodegenerative2 effects of ecstasy, and further research is clearly required. Potential hazards can also, however, arise through use of tablets sold as ecstasy that contain substances other than ecstasy, such as ketamine. Ketamine is an anaesthetic agent with a rapid action that has medical and veterinary applications. Drug users who...